{"Title": ["2 Top Small-Cap Stocks to Buy Right Now", "Is Arrowhead Pharmaceuticals a Buy?", "Is Alnylam Pharmaceuticals a Buy?", "Dicerna Pharmaceuticals Inc (DRNA) Q1 2020 Earnings Call Transcript", "11 Small-Cap Stocks Analysts Love the Most", "2 Top Small-Cap Stocks to Buy Right Now", "Better Buy: Alnylam Pharmaceuticals vs. Vir Biotechnology", "Alnylam, Dicerna Form RNAi Therapeutics Collaboration For Alpha-1 Liver Disease", "2 Top Small-Cap Stocks to Buy Right Now", "Health Care Sector Update for 03/19/2020: DRNA,SNGX,VIR", "Dicerna Pharmaceuticals Inc (DRNA) Q4 2019 Earnings Call Transcript", "These 2 Stocks Will Fall After the New Year", "Here's Why Dicerna Pharmaceuticals Is Falling Today", "Here's Why Arrowhead Pharmaceuticals Is Tumbling Today", "Does a Surprise Approval Make Alnylam Pharmaceuticals a Buy?", "Healthcare Stocks That Hit New Highs (XENE, AQST, DRNA...)", "Health Care Sector Update for 03/19/2020: SAVA,DRNA,SNGX,VIR", "Health Care Sector Update for 03/19/2020: DRNA,SNGX,VIR", "Dicerna Pharmaceuticals Inc (DRNA) Q4 2019 Earnings Call Transcript", "These 2 Stocks Will Fall After the New Year", "Here's Why Dicerna Pharmaceuticals Is Falling Today", "Health Care Sector Update for 11/18/2019: KRTX, DRNA, NVO, CLBS, JNJ, PFE, ABT, MRK, AMGN", "Dicerna Pharmaceuticals Inc (DRNA) Q3 2019 Earnings Call Transcript", "The Return of M&A Activity Is Lifting These Biotech Stocks Today", "Missed the 310% Rise of Arrowhead Pharmaceuticals? Keep an Eye On This Competitor", "2 Promising Hepatitis B Drugs, 1 Clear Winner Among Investors", "Healthcare Stocks That Hit New Highs (XBIT, DRNA, CRSP...)", "KRTX Makes Giant Leap, The Medicines' Working Well, AGRX On The Move", "Here's Why Dicerna Pharmaceuticals Jumped as Much as 22.1% Today", "Health Care Sector Update for 11/18/2019: KRTX, DRNA, NVO, CLBS, JNJ, PFE, ABT, MRK, AMGN", "Dicerna Pharmaceuticals Inc (DRNA) Q3 2019 Earnings Call Transcript", "The Return of M&A Activity Is Lifting These Biotech Stocks Today", "Commit To Buy Dicerna Pharmaceuticals At $10, Earn 13.7% Annualized Using Options", "Dicerna Pharmaceuticals Inc (DRNA) Q2 2019 Earnings Call Transcript", "Dicerna Pharmaceuticals Inc (DRNA) Q1 2019 Earnings Call Transcript", "4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics", "Dicerna Pharmaceuticals Inc (DRNA) Q4 2018 Earnings Conference Call Transcript", "Dicerna Pharmaceuticals (DRNA) Reports Q4 Loss, Lags Revenue Estimates", "Healthcare Stocks That Hit New Highs ( REPH, CNMD, DRNA,...)", "Dicerna Pharmaceuticals (DRNA) Reports Q3 Loss, Misses Revenue Estimates", "Bluebird Bio Stock May Have Upside of at Least 60 Percent", "Health Care Sector Update for 09/07/2018: DRNA, PRQR, TMO, AKCA, BSX, IRIX", "Here's Why Dicerna Pharmaceuticals, Inc. Is on a Roller Coaster; Down 18% Yesterday, Up 17% Today", "Dicerna Pharmaceuticals (DRNA) Reports Q2 Loss, Misses Revenue Estimates", "Will ACADIA (ACAD) Disappoint Investors in Q2 Earnings?", "AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?", "After-Hours Earnings Report for March 11, 2019 : ADT, COUP, SFIX, DRNA, AVD, PETQ, CCXI, LXFR, MG, OXFD, FRTA, KALA", "After-Hours Earnings Report for May 14, 2018 : A, INVH, VIPS, RXN, ITRI, MIME, AY, HOLI, FPH, TDW, DRNA, CORI", "Health Care Sector Update for 04/23/2018: DRNA,ALNY,HSIC,BHVN,AKRX,FMS", "Why Dicerna Rocketed Higher Today", "4 Drug Stocks to Watch", "Cerner's EHR Platform to Enhance Health Care at San Juan NGO", "Kindred Biosciences (KIN) Looks Good: Stock Jumps 9.5%", "Barnes & Noble, Inc. Leads 5 Activist Investor Filings (BKS)", "4 Sell-Ranked Drug Stocks Investors Should Avoid Ahead of Earnings", "After-Hours Earnings Report for March 30, 2017 : FC, AEHR, MARK, DRNA, STKS, UNXL, UQM, MARA", "Can The Uptrend Continue for Dicerna Pharmaceuticals (DRNA)?", "Dicerna Pharmaceuticals (DRNA) Rises: Stock Climbs 14%", "Stocks Most Likely to Beat Earnings for the week of February 13th", "Monday Sector Leaders: Biotechnology, Drugs", "Dicerna Pharmaceuticals (DRNA) Rises: Stock Gains 7.8%", "Array BioPharma (ARRY) Jumps: Stock Adds 7.5% in Session", "Dicerna Pharmaceuticals (DRNA) Worth a Look: Stock Up 6%", "Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 7.5%", "Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 8.7%", "Alnylam Begins Study for Primary Hyperoxaluria Type 1", "Alnylam Submits Clinical Trial Application for ALN-GO1 in UK", "Monday Sector Leaders: Biotechnology, Drugs", "Dicerna Pharmaceuticals (DRNA) Rises: Stock Gains 7.8%", "Array BioPharma (ARRY) Jumps: Stock Adds 7.5% in Session", "More capital for Canadian cancer cures: ProNAi Therapeutics increases proposed IPO deal size by 37%", "Canadian cancer biotech ProNAi Therapeutics sets terms for $101 million IPO", "Something good out of Canada: Cancer biotech ProNAi Therapeutics files for an $86 million IPO", "Health Care Sector Update for 06/11/2015: DRNA,ALNY,MRK,PTBI,PBMD", "Health Care Sector Update for 05/21/2015: CALA, DRNA, REGN", "Why Shares Of Dicerna Pharmaceuticals Are Down Today", "Alnylam to Speed Up Development for Primary Hyperoxaluria", "The harder they fall: high-popping IPOs hammered in aftermarket trading", "US IPO Recap: Varonis provides data security for enterprises and financial security for investors", "Biotechs dominate IPO calendar, but most post negative returns", "US IPO Recap: Ultragenyx doubles and Dicerna triples in home-run week for biotech IPOs", "Dicerna gains 207% in market debut, best biotech first-day pop since 2000", "Biotech boomlet set to smash IPO record for two-week period", "Healthcare Stocks Ending on High Note; Dicerna Pharma Almost Triples in Value After $90 Mln IPO", "Sector Update: Healthcare", "Dicerna Pharmaceuticals prices IPO at $15, above the upwardly revised range", "Dicerna Pharmaceuticals increases shares offered and range, deal size is now $84 million", "6 US IPOs planned for the week of Jan 27", "Cancer biotech Dicerna Pharmaceuticals sets terms for $60 million IPO", "US IPO Recap: IMS Health files for potential billion-dollar offering", "Cancer biotech Dicerna Pharmaceuticals files for a $69 million IPO", "Sector Update: Healthcare"], "Elapsed Time": ["JUN 12, 2020", "MAY 24, 2020", "MAY 21, 2020", "MAY 9, 2020", "MAY 7, 2020", "APR 15, 2020", "APR 12, 2020", "APR 6, 2020", "JUN 12, 2020", "MAR 19, 2020", "FEB 28, 2020", "JAN 3, 2020", "DEC 20, 2019", "DEC 4, 2019", "DEC 3, 2019", "DEC 3, 2019", "MAR 19, 2020", "MAR 19, 2020", "FEB 28, 2020", "JAN 3, 2020", "DEC 20, 2019", "NOV 18, 2019", "NOV 7, 2019", "NOV 25, 2019", "NOV 21, 2019", "NOV 20, 2019", "NOV 19, 2019", "NOV 19, 2019", "NOV 18, 2019", "NOV 18, 2019", "NOV 7, 2019", "NOV 25, 2019", "SEP 30, 2019", "AUG 9, 2019", "MAY 9, 2019", "APR 11, 2019", "MAR 11, 2019", "MAR 11, 2019", "NOV 1, 2019", "NOV 5, 2018", "SEP 12, 2018", "SEP 7, 2018", "SEP 7, 2018", "AUG 8, 2018", "JUL 31, 2018", "JUL 31, 2018", "MAR 11, 2019", "MAY 14, 2018", "APR 23, 2018", "APR 20, 2018", "JAN 24, 2018", "FEB 13, 2017", "JAN 16, 2017", "APR 21, 2017", "APR 20, 2017", "MAR 30, 2017", "FEB 22, 2017", "FEB 16, 2017", "DEC 22, 2015", "NOV 2, 2015", "SEP 21, 2015", "JAN 16, 2017", "SEP 22, 2016", "AUG 16, 2016", "MAY 23, 2016", "MAR 10, 2016", "DEC 22, 2015", "NOV 2, 2015", "SEP 21, 2015", "JAN 16, 2017", "JUL 15, 2015", "JUL 6, 2015", "JUN 12, 2015", "JUN 11, 2015", "MAY 21, 2015", "MAY 21, 2015", "SEP 9, 2015", "APR 10, 2014", "MAR 3, 2014", "FEB 6, 2014", "FEB 3, 2014", "JAN 30, 2014", "JAN 30, 2014", "JAN 30, 2014", "JUN 30, 2014", "JAN 29, 2014", "JAN 28, 2014", "JAN 27, 2014", "JAN 21, 2014", "JAN 6, 2014", "JAN 2, 2014", "JAN 30, 2014"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/2-top-small-cap-stocks-to-buy-right-now-2020-06-12", "https://www.nasdaq.com/articles/is-arrowhead-pharmaceuticals-a-buy-2020-05-24", "https://www.nasdaq.com/articles/is-alnylam-pharmaceuticals-a-buy-2020-05-21", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-inc-drna-q1-2020-earnings-call-transcript-2020-05-09", "https://www.nasdaq.com/articles/11-small-cap-stocks-analysts-love-the-most-2020-05-07", "https://www.nasdaq.com/articles/2-top-small-cap-stocks-to-buy-right-now-2020-04-15", "https://www.nasdaq.com/articles/better-buy%3A-alnylam-pharmaceuticals-vs.-vir-biotechnology-2020-04-12", "https://www.nasdaq.com/articles/alnylam-dicerna-form-rnai-therapeutics-collaboration-for-alpha-1-liver-disease-2020-04-06", "https://www.nasdaq.com/articles/2-top-small-cap-stocks-to-buy-right-now-2020-06-12", "https://www.nasdaq.com/articles/health-care-sector-update-for-03-19-2020%3A-drnasngxvir-2020-03-19", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-inc-drna-q4-2019-earnings-call-transcript-2020-02-28", "https://www.nasdaq.com/articles/these-2-stocks-will-fall-after-the-new-year-2020-01-03", "https://www.nasdaq.com/articles/heres-why-dicerna-pharmaceuticals-is-falling-today-2019-12-20", "https://www.nasdaq.com/articles/heres-why-arrowhead-pharmaceuticals-is-tumbling-today-2019-12-04", "https://www.nasdaq.com/articles/does-a-surprise-approval-make-alnylam-pharmaceuticals-a-buy-2019-12-03", "https://www.nasdaq.com/articles/healthcare-stocks-that-hit-new-highs-xene-aqst-drna...-2019-12-03", "https://www.nasdaq.com/articles/health-care-sector-update-for-03-19-2020%3A-savadrnasngxvir-2020-03-19", "https://www.nasdaq.com/articles/health-care-sector-update-for-03-19-2020%3A-drnasngxvir-2020-03-19", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-inc-drna-q4-2019-earnings-call-transcript-2020-02-28", "https://www.nasdaq.com/articles/these-2-stocks-will-fall-after-the-new-year-2020-01-03", "https://www.nasdaq.com/articles/heres-why-dicerna-pharmaceuticals-is-falling-today-2019-12-20", "https://www.nasdaq.com/articles/health-care-sector-update-for-11-18-2019%3A-krtx-drna-nvo-clbs-jnj-pfe-abt-mrk-amgn-2019-11", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-inc-drna-q3-2019-earnings-call-transcript-2019-11-08", "https://www.nasdaq.com/articles/the-return-of-ma-activity-is-lifting-these-biotech-stocks-today-2019-11-25", "https://www.nasdaq.com/articles/missed-the-310-rise-of-arrowhead-pharmaceuticals-keep-an-eye-on-this-competitor-2019-11-21", "https://www.nasdaq.com/articles/2-promising-hepatitis-b-drugs-1-clear-winner-among-investors-2019-11-20", "https://www.nasdaq.com/articles/healthcare-stocks-that-hit-new-highs-xbit-drna-crsp...-2019-11-19", "https://www.nasdaq.com/articles/krtx-makes-giant-leap-the-medicines-working-well-agrx-on-the-move-2019-11-19", "https://www.nasdaq.com/articles/heres-why-dicerna-pharmaceuticals-jumped-as-much-as-22.1-today-2019-11-18", "https://www.nasdaq.com/articles/health-care-sector-update-for-11-18-2019%3A-krtx-drna-nvo-clbs-jnj-pfe-abt-mrk-amgn-2019-11", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-inc-drna-q3-2019-earnings-call-transcript-2019-11-08", "https://www.nasdaq.com/articles/the-return-of-ma-activity-is-lifting-these-biotech-stocks-today-2019-11-25", "https://www.nasdaq.com/articles/commit-to-buy-dicerna-pharmaceuticals-at-%2410-earn-13.7-annualized-using-options-2019-09-30", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-inc-drna-q2-2019-earnings-call-transcript-2019-08-10", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-inc-drna-q1-2019-earnings-call-transcript-2019-05-10", "https://www.nasdaq.com/articles/4-drugbiotech-stocks-making-mark-rnai-therapeutics-2019-04-11-0", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-inc-drna-q4-2018-earnings-conference-call-transcript-2019-03-11", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-drna-reports-q4-loss-lags-revenue-estimates-2019-03-11", "https://www.nasdaq.com/articles/healthcare-stocks-that-hit-new-highs-reph-cnmd-drna...-2019-11-01", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-drna-reports-q3-loss-misses-revenue-estimates-2018-11-05", "https://www.nasdaq.com/articles/bluebird-bio-stock-may-have-upside-least-60-percent-2018-09-12", "https://www.nasdaq.com/articles/health-care-sector-update-09072018-drna-prqr-tmo-akca-bsx-irix-2018-09-07", "https://www.nasdaq.com/articles/heres-why-dicerna-pharmaceuticals-inc-roller-coaster-down-18-yesterday-17-today-2018-09-07", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-drna-reports-q2-loss-misses-revenue-estimates-2018-08-08", "https://www.nasdaq.com/articles/will-acadia-acad-disappoint-investors-in-q2-earnings-2018-07-31", "https://www.nasdaq.com/articles/aveo-pharmaceuticals-aveo-q2-earnings%3A-whats-in-store-2018-07-31", "https://www.nasdaq.com/articles/after-hours-earnings-report-march-11-2019-adt-coup-sfix-drna-avd-petq-ccxi-lxfr-mg-oxfd", "https://www.nasdaq.com/articles/after-hours-earnings-report-may-14-2018-invh-vips-rxn-itri-mime-ay-holi-fph-tdw-drna-cori", "https://www.nasdaq.com/articles/health-care-sector-update-04232018-drnaalnyhsicbhvnakrxfms-2018-04-23", "https://www.nasdaq.com/articles/why-dicerna-rocketed-higher-today-2018-04-20", "https://www.nasdaq.com/articles/4-drug-stocks-watch-2018-01-24", "https://www.nasdaq.com/articles/cerners-ehr-platform-to-enhance-health-care-at-san-juan-ngo-2017-02-13", "https://www.nasdaq.com/articles/kindred-biosciences-kin-looks-good%3A-stock-jumps-9.5-2017-01-16", "https://www.nasdaq.com/articles/barnes-noble-inc.-leads-5-activist-investor-filings-bks-2017-04-21", "https://www.nasdaq.com/articles/4-sell-ranked-drug-stocks-investors-should-avoid-ahead-earnings-2017-04-20", "https://www.nasdaq.com/articles/after-hours-earnings-report-march-30-2017-fc-aehr-mark-drna-stks-unxl-uqm-mara-2017-03-30", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-dicerna-pharmaceuticals-drna-2017-02-22", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-drna-rises%3A-stock-climbs-14-2017-02-16", "https://www.nasdaq.com/articles/alnylam-submits-clinical-trial-application-for-aln-go1-in-uk-2015-12-22", "https://www.nasdaq.com/articles/monday-sector-leaders-biotechnology-drugs-2015-11-02", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-drna-rises%3A-stock-gains-7.8-2015-09-21", "https://www.nasdaq.com/articles/array-biopharma-arry-jumps%3A-stock-adds-7.5-in-session-2017-01-16", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-drna-worth-a-look%3A-stock-up-6-2016-09-22", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-drna-jumps%3A-stock-rises-7.5-2016-08-16", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-drna-jumps%3A-stock-rises-8.7-2016-05-23", "https://www.nasdaq.com/articles/alnylam-begins-study-for-primary-hyperoxaluria-type-1-2016-03-10", "https://www.nasdaq.com/articles/alnylam-submits-clinical-trial-application-for-aln-go1-in-uk-2015-12-22", "https://www.nasdaq.com/articles/monday-sector-leaders-biotechnology-drugs-2015-11-02", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-drna-rises%3A-stock-gains-7.8-2015-09-21", "https://www.nasdaq.com/articles/array-biopharma-arry-jumps%3A-stock-adds-7.5-in-session-2017-01-16", "https://www.nasdaq.com/articles/more-capital-canadian-cancer-cures-pronai-therapeutics-increases-proposed-ipo-deal-size-37", "https://www.nasdaq.com/articles/canadian-cancer-biotech-pronai-therapeutics-sets-terms-101-million-ipo-2015-07-06", "https://www.nasdaq.com/articles/something-good-out-canada-cancer-biotech-pronai-therapeutics-files-86-million-ipo-2015-06", "https://www.nasdaq.com/articles/health-care-sector-update-06112015-drnaalnymrkptbipbmd-2015-06-11", "https://www.nasdaq.com/articles/health-care-sector-update-05212015-cala-drna-regn-2015-05-21", "https://www.nasdaq.com/articles/why-shares-dicerna-pharmaceuticals-are-down-today-2015-05-21", "https://www.nasdaq.com/articles/alnylam-to-speed-up-development-for-primary-hyperoxaluria-2015-09-09", "https://www.nasdaq.com/articles/harder-they-fall-high-popping-ipos-hammered-aftermarket-trading-2014-04-10", "https://www.nasdaq.com/articles/us-ipo-recap-varonis-provides-data-security-enterprises-and-financial-security-investors", "https://www.nasdaq.com/articles/biotechs-dominate-ipo-calendar-most-post-negative-returns-2014-02-06", "https://www.nasdaq.com/articles/us-ipo-recap-ultragenyx-doubles-and-dicerna-triples-home-run-week-biotech-ipos-2014-02-03", "https://www.nasdaq.com/articles/dicerna-gains-207-market-debut-best-biotech-first-day-pop-2000-2014-01-30", "https://www.nasdaq.com/articles/biotech-boomlet-set-smash-ipo-record-two-week-period-2014-01-30", "https://www.nasdaq.com/articles/healthcare-stocks-ending-high-note-dicerna-pharma-almost-triples-value-after-90-mln-ipo", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-06-30-1", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-prices-ipo-15-above-upwardly-revised-range-2014-01-29", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-increases-shares-offered-and-range-deal-size-now-84-million-2014", "https://www.nasdaq.com/articles/6-us-ipos-planned-week-jan-27-2014-01-27", "https://www.nasdaq.com/articles/cancer-biotech-dicerna-pharmaceuticals-sets-terms-60-million-ipo-2014-01-21", "https://www.nasdaq.com/articles/us-ipo-recap-ims-health-files-potential-billion-dollar-offering-2014-01-06", "https://www.nasdaq.com/articles/cancer-biotech-dicerna-pharmaceuticals-files-69-million-ipo-2014-01-02", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-01-30-0"], "Content": []}